Silencing of Survivin Using YM155 Inhibits Invasion and Suppresses Proliferation in Glioma Cells

Cell Biochemistry and Biophysics

Volumn 71, Issue 2, 2015, Pages 587-593

  Guo, Hua ^a   Wang, Yuexun ^b   Song, Tao ^a   Xin, Tao ^a   Zheng, Zhiming ^a   Zhong, Peng ^a   Zhang, Xiaoli ^c  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b Jining First People's Hospital   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

GBM; Invasion; Migration; Survivin; YM155

Indexed keywords

BIRC5 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; NAPHTHOQUINONE; SEPANTRONIUM BROMIDE;

ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GLIOMA; HUMAN; METABOLISM; NERVE CELL; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GLIOMA; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; NAPHTHOQUINONES; NEURONS;

EID: 84922540323     PISSN: 10859195     EISSN: 15590283     Source Type: Journal    
DOI: 10.1007/s12013-014-0238-4     Document Type: Article

References (35)

1. Surawicz, T. S., et al. (1998). Brain tumor survival: results from the National Cancer Data Base. Journal of Neuro-oncology,40(2), 151–160.
2. Grossman, S. A., & Batara, J. F. (2004). Current management of glioblastoma multiforme. Seminars in Oncology,31(5), 635–644.
3. Quick, A., et al. (2010). Current therapeutic paradigms in glioblastoma. Reviews on Recent Clinical Trials,5(1), 14–27.
4. Ambrosini, G., Adida, C., & Altieri, D. C. (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Medicine,3(8), 917–921.
5. Chakravarti, A., et al. (2002). Quantitatively determined survivin expression levels are of prognostic value in human gliomas. Journal of Clinical Oncology,20(4), 1063–1068.
6. Kajiwara, Y., et al. (2003). Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer,97(4), 1077–1083.
7. Saito, T., et al. (2007). Survivin subcellular localization in high-grade astrocytomas: Simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. Journal of Neuro-oncology,82(2), 193–198.
8. George, J., Banik, N. L., & Ray, S. K. (2010). Survivin knockdown and concurrent 4-HPR treatment controlled human glioblastoma in vitro and in vivo. Neuro-Oncology,12(11), 1088–1101.
9. Kang, D. W., et al. (2008). Ciglitazone induces caspase-independent apoptosis through down-regulation of XIAP and survivin in human glioma cells. Neurochemical Research,33(3), 551–561.
10. Kardosh, A., et al. (2007). Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib. Journal of Biomedical Science,14(5), 647–662.
11. Blum, R., et al. (2006). Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Molecular Cancer Therapeutics,5(9), 2337–2347.
12. Schultze, K., et al. (2006). Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis,11(9), 1503–1512.
13. Nakahara, T., et al. (2007). YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Research,67(17), 8014–8021.
14. Wang, Q., et al. (2011). Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells. Cancer Letters,302(1), 29–36.
15. Nakahara, T., et al. (2011). YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anti-Cancer Drugs,22(5), 454–462.
16. Iwasa, T., et al. (2008). Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clinical Cancer Research,14(20), 6496–6504.
17. Zhang, Y., et al. (2009). siRNA targeting survivin inhibits growth and induces apoptosis in human renal clear cell carcinoma 786-O cells. Pathology, Research and Practice,205(12), 823–827.
18. Lai, P. C., et al. (2012). Novel survivin inhibitor YM155 elicits cytotoxicity in glioblastoma cell lines with normal or deficiency DNA-dependent protein kinase activity. Pediatrics and Neonatology,53(3), 199–204.
19. Qin, F. X., et al. (2011). Knockdown of NPM1 by RNA interference inhibits cells proliferation and induces apoptosis in leukemic cell line. International Journal of Medical Sciences,8(4), 287–294.
20. Liao, W., et al. (2013). Silencing of DLGAP5 by siRNA significantly inhibits the proliferation and invasion of hepatocellular carcinoma cells. PLoS ONE,8(12), e80789.
21. Walter, M. N., et al. (2010). Mesenchymal stem cell-conditioned medium accelerates skin wound healing: an in vitro study of fibroblast and keratinocyte scratch assays. Experimental Cell Research,316(7), 1271–1281.
22. Lin, G. S., et al. (2014). STAT3 serine 727 phosphorylation influences clinical outcome in glioblastoma. International Journal of Clinical and Experimental Pathology,7(6), 3141–3149.
23. Ostrom, Q. T., et al. (2013). CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-Oncology, 15(Suppl 2), ii1–56.
24. Stupp, R., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine,352(10), 987–996.
25. Velculescu, V. E., et al. (1999). Analysis of human transcriptomes. Nature Genetics,23(4), 387–388.
26. O’Connor, D. S., et al. (2000). Control of apoptosis during angiogenesis by survivin expression in endothelial cells. American Journal of Pathology,156(2), 393–398.
27. Shin, S., et al. (2001). An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry,40(4), 1117–1123.
28. Liu, T., Brouha, B., & Grossman, D. (2004). Rapid induction of mitochondrial events and caspase-independent apoptosis in survivin-targeted melanoma cells. Oncogene,23(1), 39–48.
29. Li, F., et al. (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. Nature,396(6711), 580–584.
30. Mirza, A., et al. (2002). Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene,21(17), 2613–2622.
31. Hoffman, W. H., et al. (2002). Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. Journal of Biological Chemistry,277(5), 3247–3257.
32. Pennati, M., Folini, M., & Zaffaroni, N. (2008). Targeting survivin in cancer therapy. Expert Opinion on Therapeutic Targets,12(4), 463–476.
33. Or, Y. Y., et al. (2014). Survivin depletion inhibits tumor growth and enhances chemosensitivity in hepatocellular carcinoma. Molecular Medicine Reports. doi:10.3892/mmr.2014.2413.
34. Dohi, T., Xia, F., & Altieri, D. C. (2007). Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Molecular Cell,27(1), 17–28.
35. Mehrotra, S., et al. (2010). IAP regulation of metastasis. Cancer Cell,17(1), 53–64.